6.6.3. first-line hormonal treatment. primary adt soc 50 years . high-level evidence favour specific type adt oncological outcomes, neither orchiectomy lhrh agonist antagonist. level testosterone reduced much faster orchiectomy lhrh antagonist, therefore patients impending spinal cord compression potential impending complications cancer treated either bilateral orchidectomy lhrh antagonists preferred options. suggestion studies sr meta-analysis cardiovascular side effects less frequent patients treated lhrh antagonists patients treated lhrh agonists [1053,1097-1099]; therefore, patients pre-existing cardiovascular disease cardiovascular risk factors might considered treated antagonists chemical castration chosen. 6.6.3.1. non-steroidal anti-androgen monotherapy based cochrane review comparing older generation non-steroidal anti-androgen (nsaa) monotherapy adt (either medical surgical), nsaa considered less effective terms os, clinical progression, treatment failure treatment discontinuation due aes generally recommended also adt-based combination treatments become soc. 6.6.3.2. intermittent versus continuous androgen deprivation therapy three independent reviews [1101-1103] two meta-analyses looked clinical efficacy intermittent androgen deprivation (iad) therapy. reviews included eight rcts three conducted patients exclusively m1 disease. far, swog 9346 largest trial addressing iad m1b patients . 3,040 screened patients, 1,535 patients met inclusion criteria. highlights 50% m1b patients expected candidates iad, i.e. best psa responders. non-inferiority trial leading inconclusive results: actual upper limit pre-specified 90% upper limit 1.2 (hr: 1.1, ci: 0.99â€“1.23), pre-specified non-inferiority limit achieved, results show significant inferiority treatment arm. however, based study inferior survival iad cannot completely ruled even highly selected subgroup. use intermittent adt superseeded continuous adt based combination therapy become soc. 6.6.3.3. early versus deferred androgen deprivation therapy early treatment onset symptoms recommended majority patients metastatic hormone-sensitive disease despite lack randomised phase iii data specific setting specifically combination therapies standard nowadays. cochrane analysis 2019 topic concluded early adt probably extends time death cause time death pca . since analysis included limited number metastatic patients, benefit early adt setting remains unproven. trials testing combination therapies metastatic hormone-sensitive setting also included asymptomatic patients. candidates metastatic disease may possibly considered deferred treatment asymptomatic patients strong wish avoid treatment-related side effects. risk developing symptoms, even dying pca, without receiving benefit adt deferred treatment highlighted , era next generation imaging used. patients deferred treatment advanced pca must amenable close follow-up. another potential exception patients recurrent oligometastatic disease strong wish postpone start adt (see section 6.4.7).